The day a bench trial was slated to begin in Delaware federal court on Gilead’s five patent disputes with generic drug makers who were poised and ready to make copies of Gilead’s two HIV blockbuster drugs and its hepatitis B drug, the company announced that it had settled the disputes.
Source: Drug Industry Daily